Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
16.28
-0.76 (-4.46%)
Nov 12, 2026, 4:00 PM EST - Market closed
Aktis Oncology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 68.32 | 37.78 | 37.16 | 29.51 | 128.6 |
Short-Term Investments | 424.61 | 189 | 260.01 | 68.35 | - |
Cash & Short-Term Investments | 492.93 | 226.79 | 297.17 | 97.86 | 128.6 |
Cash Growth | 100.20% | -23.68% | 203.66% | -23.90% | - |
Other Receivables | - | 1.1 | 1.1 | 0.3 | - |
Receivables | - | 1.1 | 1.1 | 0.3 | - |
Prepaid Expenses | 6.96 | 2.42 | 2.59 | 2.04 | 3.88 |
Total Current Assets | 499.89 | 230.31 | 300.85 | 100.2 | 132.48 |
Property, Plant & Equipment | 27.11 | 27.25 | 20.87 | 20.92 | 4.87 |
Other Long-Term Assets | 5.49 | 7.33 | 4.46 | 1.23 | 0.98 |
Total Assets | 532.48 | 264.89 | 326.18 | 122.36 | 138.32 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 1.44 | 1.74 | 1.92 | 0.96 | 0.49 |
Accrued Expenses | 17.04 | 9.52 | 6.33 | 3.75 | 3.93 |
Current Portion of Leases | 1.46 | 1.32 | 1.3 | 1.53 | 0.85 |
Current Unearned Revenue | 15.23 | 18.66 | 9.28 | - | - |
Total Current Liabilities | 35.16 | 31.24 | 18.82 | 6.24 | 5.28 |
Long-Term Leases | 9.38 | 10.23 | 10.71 | 11.87 | 0.92 |
Long-Term Unearned Revenue | 29.07 | 36.16 | 51.04 | - | - |
Other Long-Term Liabilities | - | - | - | 0.5 | 1.31 |
Total Liabilities | 73.61 | 77.63 | 80.58 | 18.61 | 7.5 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Additional Paid-In Capital | 689.77 | 10.37 | 4.91 | 2.47 | 0.98 |
Retained Earnings | -228.97 | -156.56 | -92.83 | -48.85 | -20.21 |
Comprehensive Income & Other | -1.93 | 0.04 | 0.12 | 0.08 | - |
Total Common Equity | 458.87 | -146.15 | -87.8 | -46.31 | -19.23 |
Shareholders' Equity | 458.87 | 187.26 | 245.61 | 103.74 | 130.82 |
Total Liabilities & Equity | 532.48 | 264.89 | 326.18 | 122.36 | 138.32 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 10.84 | 11.55 | 12.01 | 13.4 | 1.78 |
Net Cash (Debt) | 482.09 | 215.24 | 285.16 | 84.46 | 126.82 |
Net Cash Growth | 105.71% | -24.52% | 237.63% | -33.40% | - |
Net Cash Per Share | 12.02 | 264.58 | 404.96 | 137.29 | 245.11 |
Filing Date Shares Outstanding | 55.8 | 55.28 | 0.78 | 0.65 | 0.52 |
Total Common Shares Outstanding | 55.78 | 0.92 | 0.78 | 0.65 | 0.52 |
Working Capital | 464.73 | 199.07 | 282.03 | 93.97 | 127.21 |
Book Value Per Share | 8.23 | -159.68 | -112.42 | -71.27 | -37.17 |
Tangible Book Value | 458.87 | -146.15 | -87.8 | -46.31 | -19.23 |
Tangible Book Value Per Share | 8.23 | -159.68 | -112.42 | -71.27 | -37.17 |
Machinery | - | 12.75 | 8.81 | 6.4 | 2.74 |
Construction In Progress | - | 7.01 | 1.33 | 0.4 | 0.56 |
Leasehold Improvements | - | 0.17 | 0.17 | 0.17 | 0.17 |